Table 3.
IC50 values of CRY administered as pure compound or as ULV and MLV formulations in HepG2 and MDA-MB-468 cells.
| HepG2 | MDA-MB-468 | |
|---|---|---|
| IC50 (CL) μg/mL RR | ||
| CRY | 44.7 (19.5–96.8) | 19.2 (15.4–23.8) |
| SPC/CRY ULV (mol/mol) | ||
| 1:0.1 | ne | 12.4 (6.4–109.9) 1.5 |
| 1:0.3 | ne | ne |
| 1:0.5 | ne | ne |
| SPC/CRY MLV (mol/mol) | ||
| 1:0.1 | ne | 4.9 (2.4–9.9) 3.9 |
| 1:0.3 | 9.1 (2.6–32.0) 4.9 |
8.3 (6.1–11.2) 2.3 |
| 1:0.5 | ne | ne |
CL, confidential limits; RR, reversal ratio (ratio between the IC50 values of CRY alone and CRY-loaded SPC liposomes); ne, not evaluable as a lower than 80% inhibition of cell viability was reached.